Navigation Links
Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water
Date:7/16/2009

ST. LOUIS, July 16 /PRNewswire-FirstCall/ -- Supelco, a division of Sigma-Aldrich (Nasdaq: SIAL), and MIP Technologies AB announced today the launch of a new molecularly imprinted polymer, SPE product, SupelMIP(TM), for the selective extraction of non-steroidal anti-inflammatory drugs (NSAIDs).

"SupelMIP NSAIDS is an important addition to our portfolio because it targets a critical area of public concern - the increasing appearance of prescription and over-the-counter drugs in environmental water," said Anthony Rees, CEO of MIP Technologies. "This concern is reflected in the programs initiated by many governments to monitor national water resources for the presence and concentrations of the most frequently used drugs having the potential for adverse effects. This product recognizes members of the class of NSAIDs related to ibuprofen and will simplify the analysis of these drugs when present, at even low levels, in natural water samples."

SupelMIP was developed for confirmation and quantitation of NSAID drugs in water samples. The SPE phase has been developed for multi-residue extraction of NSAIDs and has been validated for ibuprofen, diclofenac, naproxen, clofibric acid, celecoxob and piroxicam.

"SupelMIP SPE allows researchers to selectively extract and recover non-steroidal anti-inflammatory drugs," said An Trinh, product manager of Sample Prep at Supelco. "Such compounds are among the most highly consumed pharmaceuticals in the world."

Ibuprofen, diclofenac and naproxen are non-steroidal anti-inflammatory drugs that have analgesic and antipyretic activities. Clofibric acid is an active metabolite of clofibrate, etofibrate and etofyllinclofibrate. These compounds are used as blood lipid regulators. Because of the pharmacological activity of the NSAIDs and the possibility of entry into the domestic water cycle, the concentrations need to be accurately quantified in natural water samples.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About MIP Technologies: MIP Technologies AB is a world-leading company in the development of molecularly imprinted polymers (MIPs) and other novel polymers. The Company is a pioneer in the commercial applications of MIPs, holds important patents and maintains cutting-edge research activities in this area. The Company's mission is to provide innovative products based on molecularly imprinted polymers that serve industry's needs in analytical, preparative and process scale 'selective separations'. The Company has the ability to produce MIPs and other selective polymers from laboratory to pilot scale and is well placed to develop large-scale separation solutions for its customers. Currently, the Company develops analytical separation products (e.g. SPE) and has multiple custom process scale projects in place with several blue chip companies. MIP Technologies has its headquarters in Lund, Sweden. For more information about MIP Technologies AB visit www.miptechnologies.com

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich and Supelco are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. Supel-MIP is a trademark of Supelco.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Supelco(R) Expands Ascentis(R) Express HPLC Columns Line for High-Speed and High-Efficiency Separations
2. Supelco(R) Introduces Ascentis(R) Express HILIC HPLC Columns for High-Speed and High-Efficiency Separations
3. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
4. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
5. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
6. IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
7. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
8. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
9. Greenway Medical Technologies To Display Live Interoperability Implementations at 2009 DIA Show
10. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
11. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):